Puma Biotechnology (PBYI) Earnings Date & Reports

Key Takeaways

• Puma Biotechnology reported third quarter 2026 GAAP net income of $6.0 million, or $0.11 per diluted share, with non-GAAP net income of $8.0 million, or $0.15 per share.
• Total revenue of $55.1 million came in below the consensus estimate of roughly $57.5 million, while NERLYNX net product revenue rose to $54.1 million from $53.6 million in the prior quarter.
• Management raised full-year 2026 net income guidance to $20–$22 million, up from a prior range of $17–$20 million.
• U.S. NERLYNX demand softened sequentially, with new prescriptions and patient enrollments declining despite year-over-year growth in overall demand.
• The company ended the quarter with $108.5 million in cash and marketable securities and no debt outstanding after retiring its remaining obligations earlier in the year.
• For more context on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages for deeper analysis.
• Investors looking for additional ideas can explore Trending AI Robots to follow AI-driven trading strategies across the market.

Earnings Context and Why It Matters

Puma Biotechnology is a biopharmaceutical company built around NERLYNX (neratinib), its approved treatment for HER2-positive breast cancer, and a growing pipeline led by alisertib, an investigational Aurora Kinase A inhibitor. Because NERLYNX is the company's primary commercial product, each quarterly report offers investors a direct read on U.S. demand, reimbursement dynamics, and gross-to-net pricing trends. The third quarter also carried added weight as management works to balance near-term profitability against increased research and development spending. With the company having recently eliminated its debt and improved its balance sheet, this earnings print was closely watched for signs of whether commercial momentum could sustain the stock's strong run and whether pipeline investment would pressure margins.

Reported Results

For the third quarter ended September 30, 2026, Puma Biotechnology reported total revenue of $55.1 million, including NERLYNX net product revenue of $54.1 million and royalty revenue of approximately $1.0 million. NERLYNX net product revenue increased from $53.6 million in the second quarter of 2026 and from $51.9 million in the third quarter of 2025, though the quarter benefited from roughly $3.6 million of ex-U.S. product supply revenue.

On the bottom line, the company posted GAAP net income of $6.0 million, or $0.11 per diluted share, compared with $8.2 million, or $0.16 per share, in the prior quarter. Non-GAAP net income, which excludes stock-based compensation expense, was $8.0 million, or $0.15 per share. While earnings exceeded consensus expectations, total revenue landed below the analyst estimate of approximately $57.5 million. Management also narrowed full-year 2026 total revenue guidance to $224–$227 million while raising its net income outlook to $20–$22 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. For investors tracking earnings-driven movers like Puma Biotechnology, the AI Screener offers a practical way to surface comparable opportunities across the biotech and pharmaceutical landscape.

Market Reaction and Investor Sentiment

Investor reaction to the third quarter report reflected a mixed picture. The earnings beat and raised profitability guidance were offset by a top-line miss and signs of slowing U.S. NERLYNX demand. Underlying volume data showed U.S. demand of 2,899 bottles, down 3% sequentially, while new prescriptions declined 13% and patient enrollments fell 12%. A sequential drop in sales call activity, tied partly to territory vacancies, added an execution concern for the commercial team. At the same time, a cleaner balance sheet, improved operating cash flow of $14.6 million, and the absence of debt provided supportive signals that helped temper the weaker demand narrative.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will focus on whether Puma Biotechnology can reaccelerate NERLYNX demand in the fourth quarter, which carries a heavier revenue and net income load under current guidance. The company guided to fourth quarter total revenue of roughly $67–$70 million, including a meaningful royalty contribution, along with net income of $10–$12 million.

Gross-to-net pricing dynamics remain a key swing factor. Management raised its full-year gross-to-net adjustment assumption to 27.5%–28%, reflecting a larger mix of Medicaid and 340B purchases, and guided the fourth quarter toward 28%–29%. Any further erosion in realized pricing could pressure revenue even if bottle volumes stabilize.

The alisertib pipeline is another important watch item. Puma recently initiated a second trial in advanced small cell lung cancer and expects additional interim data from its ALISCA-Lung 1 study and initial data from ALISCA-Lung 2 in 2027. Rising research and development spending tied to these programs is a central reason operating income declined year over year, and investors will monitor how efficiently those investments convert into clinical milestones.

Finally, the company has signaled interest in in-licensing or acquiring commercial-stage or development-stage assets to diversify beyond NERLYNX. Any such transaction could reshape both the pipeline and the balance sheet, making it a potential catalyst worth watching in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations